In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions
about
Use of rifaximin in gastrointestinal and liver diseasesTravelers with sickle cell diseaseRapid biosensor for detection of antibiotic-selective growth of Escherichia coliAntibiotic resistance in diarrheagenic Escherichia coli and Shigella strains isolated from children in Hanoi, Vietnam.Bile acids improve the antimicrobial effect of rifaximin.Drug prophylaxis for travelers' diarrhea.Travelers' diarrhea: antimicrobial therapy and chemoprevention.In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficileExpert review of the evidence base for prevention of travelers' diarrhea.Expert review of the evidence base for self-therapy of travelers' diarrhea.Rifaximin for the treatment of acute infectious diarrheaRifaximin: a new treatment for travelers' diarrhea.Rifaximin in the treatment of infectious diarrhea.Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Current and future developments in travelers' diarrhea therapy.Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseasesThe role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.Rifaximin therapy of irritable bowel syndrome.Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.Biologic properties and clinical uses of rifaximin.Rifaximin for the treatment of irritable bowel syndrome.Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.Rifaximin: beyond the traditional antibiotic activity.The practice of travel medicine: guidelines by the Infectious Diseases Society of America.Rifaximin for the treatment of hepatic encephalopathy.[What should be used for salmonella and company? Antibiotic therapy for bacterial diarrhea]Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial.Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Travellers' Diarrhea.
P2860
Q26740201-71373E35-623C-4FD7-B007-2F55AEA9EF1AQ30209675-B9C9074E-13C6-4592-AB84-D1A2E3282B68Q33769816-F381959A-BC86-4E46-A2D1-D82F3C577D24Q33806109-1135ECE0-64DC-4282-AE48-135CE868F5D7Q34108534-9FCB65F1-FEE6-464D-9564-17FE99C059B3Q34110485-3EB90378-542A-4C1E-A6D7-E13107375043Q34464671-A5CC4C62-38BE-476C-8E7C-CB3E1FF4920EQ34529094-F2E36E67-C5A0-487C-A251-748622EF7B66Q34557101-A00F449A-8371-4DCF-8098-7A69F9E64BE1Q34737357-136D0ABC-D6D2-4994-8B16-3D654239703FQ34987670-0FBCE3EE-57E2-4878-8438-52C060E14114Q34987675-63294A19-6921-4DAE-825B-90F4618AC5BEQ35090413-79857735-0715-4746-B5FA-40A659E72F5FQ35983943-C9EAC205-1D48-4421-B7E3-6C6040B590F7Q36108487-FA824757-1945-43AB-94BD-09A7B86CFE13Q36140657-22B6038E-037F-424D-B9EA-FE872408B1A9Q36337074-E35CBE4C-6446-411A-8761-055A179E5B30Q36505498-47C9A3CC-FEBA-4E39-8171-69E587EC2C9FQ36533648-5D6456FE-540A-456E-AF8A-579BD5D59585Q37412963-45F8387E-8A25-42BB-ABE7-0534E49C8088Q37704526-338297C5-0121-4D88-B794-475F3D01DA9AQ37768415-1BD90663-7820-4FD6-967E-9CDF310710EEQ37827877-AA0BB60C-ED44-4968-92BA-5A8A7D5449C3Q37976477-D447EB91-BE91-41F3-976E-47314630A59CQ38078988-6BB919C5-1B44-471E-8C84-69A7631F0077Q38237218-4D91B511-2A68-466E-AE52-96654239D4BCQ39067681-B9C92E34-5673-4B59-9967-070992ADCA49Q42792218-D27CD3C3-D7D7-4222-849B-7D0DC79F2232Q45202954-B197E154-4104-4EB8-94D5-1F886D0531CAQ46260190-7A02787C-9EF2-4504-BFC6-C5CF36DCA7BAQ50074491-E2B899A8-1957-46D6-8B75-0AD697A10103Q55193456-DF508BE2-2868-4CAD-845A-27C7C7A2C688
P2860
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro antimicrobial suscept ...... hea in four geographic regions
@ast
In vitro antimicrobial suscept ...... hea in four geographic regions
@en
type
label
In vitro antimicrobial suscept ...... hea in four geographic regions
@ast
In vitro antimicrobial suscept ...... hea in four geographic regions
@en
prefLabel
In vitro antimicrobial suscept ...... hea in four geographic regions
@ast
In vitro antimicrobial suscept ...... hea in four geographic regions
@en
P2093
P2860
P1476
In vitro antimicrobial suscept ...... hea in four geographic regions
@en
P2093
H L DuPont
J A Adachi
M P Verenkar
P2860
P304
P356
10.1128/AAC.45.1.212-216.2001
P407
P577
2001-01-01T00:00:00Z